Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?
The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is CareDx (CDNA) Outperforming Other Medical Stocks This Year?
Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx: Top Of My Shopping List For 2025
CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competition from major players like Natera, and macroeconomic factors affecting the transplant market.
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call.
CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA
NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday.
CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2
Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93.
